{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:07Z","timestamp":1787020807637,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Health Development Scientific Research Project","award":["Independent Innovation, 2020-1-2039"],"award-info":[{"award-number":["Independent Innovation, 2020-1-2039"]}]},{"name":"Beijing Health Promotion Foundation","award":["2019-09-05"],"award-info":[{"award-number":["2019-09-05"]}]},{"name":"2020 Fertility Research Program of Young and Middle-aged Physicians-China Health Promotion Foundation"},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20200301"],"award-info":[{"award-number":["QML20200301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The gonadotropin-releasing hormone (GnRH) antagonist protocol is advantageous given that it can avoid severe ovarian hyperstimulation syndrome (OHSS), especially for patients with polycystic ovary syndrome (PCOS). Basic and clinical evidence has shown that a threshold of luteinizing hormone (LH) stimulation is required for adequate follicular development and oocyte maturation. Ultra-low or high levels of LH are detrimental to pregnancy outcomes. We previously demonstrated that LH could be an indicator for the timing and dosage of antagonist administration in a retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>\n                      In this randomized, single-center, non-inferiority trial, we aim to test the hypothesis that there is no significant difference in cumulative ongoing pregnancy rates between PCOS patients stimulated with LH-based flexible protocol versus traditional flexible GnRH antagonist protocol. The primary efficacy endpoint will be the cumulative ongoing pregnancy rate per cycle. The secondary outcomes will be clinical pregnancy rate, cancelation rate, serious OHSS rate, and cost-efficiency. The cumulative ongoing pregnancy rate per cycle in PCOS women was 80%. Considering that a non-inferiority threshold should retain 80% of the clinical effect of a control treatment, a minimal clinical difference of 16% (two-sided:\n                      <jats:italic>\u03b1<\/jats:italic>\n                      , 2.5%;\n                      <jats:italic>\u03b2<\/jats:italic>\n                      , 20%) and a total of 196 patients were needed. Anticipating a 10% dropout rate, the total number of patients required was 216.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this study will provide evidence for the efficacy and safety of the LH-based flexible GnRH antagonist protocol in PCOS patients. Moreover, it evaluates the cost-efficiency of both protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry ChiCTR1800018129. Date assigned: 31 August 2018. Protocol version: 1.0 (18 July 2017)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06586-1","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T04:02:52Z","timestamp":1660363372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization: study protocol for a randomized controlled, non-inferiority trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Shan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-su","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-6801","authenticated-orcid":false,"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"issue":"2","key":"6586_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March WA, Moore VM, Willson KJ, Phillips D, Norman RJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544\u201351.","journal-title":"Hum Reprod"},{"issue":"10","key":"6586_CR2","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/humrep\/des232","volume":"27","author":"YB Okan","year":"2012","unstructured":"Okan YB, Gurkan B, Zuhal Y, Ibrahim E, Hakan Y. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067.","journal-title":"Hum Reprod"},{"issue":"6","key":"6586_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/humupd\/dmw025","volume":"22","author":"AH Balen","year":"2016","unstructured":"Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687\u2013708.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"6586_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/HYPERTENSIONAHA.120.15702","volume":"77","author":"JSS Rantakallio","year":"2021","unstructured":"Rantakallio JSS, Nevalainen JE, West SI, Ollila MM, Puukka K, Bloigu AH, et al. Association of self-reported polycystic ovary syndrome, obesity, and weight gain from adolescence to adulthood with hypertensive disorders of pregnancy: a community-based approach. Hypertension. 2021;77(3):1010\u20139.","journal-title":"Hypertension"},{"issue":"9","key":"6586_CR5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/humrep\/der214","volume":"26","author":"JR Mellembakken","year":"2011","unstructured":"Mellembakken JR, Berga SL, Kilen M, Tanbo TG, Abyholm T, Fedorcs\u00e1k P. Sustained fertility from 22 to 41 years of age in women with polycystic ovarian syndrome. Hum Reprod. 2011;26(9):2499\u2013504.","journal-title":"Hum Reprod"},{"issue":"4","key":"6586_CR6","first-page":"CD001750","volume":"4","author":"GA Hesham","year":"2016","unstructured":"Hesham GA, Mohamed AY, Reuben OA, Julie B, Wai SL, Frank JB. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4(4):CD001750.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"6586_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","volume":"23","author":"CB Lambalk","year":"2017","unstructured":"Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23(5):560\u201379.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"6586_CR8","first-page":"556","volume":"32","author":"M Toftager","year":"2017","unstructured":"Toftager M, Bogstad J, L\u00f8ssl K, Pr\u00e6torius L, Zedeler A, Bryndorf T, et al. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Hum Reprod. 2017;32(3):556\u201367.","journal-title":"Hum Reprod"},{"issue":"7","key":"6586_CR9","doi-asserted-by":"publisher","first-page":"2432.e17","DOI":"10.1016\/j.fertnstert.2011.03.083","volume":"95","author":"F Mart\u00ednez","year":"2011","unstructured":"Mart\u00ednez F, Rodr\u00edguez DB, Buxaderas R, Tur R, Mancini F, Coroleu B. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports. Fertil Steril. 2011;95(7):2432.e17\u20139.","journal-title":"Fertil Steril"},{"issue":"4","key":"6586_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.17772\/gp\/62205","volume":"87","author":"M Trenki\u0107","year":"2016","unstructured":"Trenki\u0107 M, Popovi\u0107 J, Kopitovi\u0107 V, Bjelica A, \u017divadinovi\u0107 R, Pop-Trajkovi\u0107 S. Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality. Ginekol Pol. 2016;87(4):265\u201370.","journal-title":"Ginekol Pol"},{"key":"6586_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fendo.2019.00067","volume":"10","author":"M Liu","year":"2019","unstructured":"Liu M, Liu S, Li L, Wang P, Li H, Li Y. LH levels may be used as an indicator for the time of antagonist administration in GnRH antagonist protocols-a proof-of-concept study. Front Endocrinol (Lausanne). 2019;10:67.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6586_CR12","doi-asserted-by":"publisher","first-page":"640047","DOI":"10.3389\/fendo.2021.640047","volume":"23","author":"Y Luo","year":"2021","unstructured":"Luo Y, Liu S, Su H, Hua L, Ren H, Liu M, et al. Low serum LH levels during ovarian stimulation with GnRH antagonist protocol decrease the live birth rate after fresh embryo transfers but have no impact in freeze-all cycles. Front Endocrinol (Lausanne). 2021;23:640047.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6586_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137.","journal-title":"Hum Reprod"},{"key":"6586_CR14","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"1","key":"6586_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/jhrs.JHRS_59_20","volume":"14","author":"N Singh","year":"2021","unstructured":"Singh N, Mishra N, Dogra Y. Do basal luteinizing hormone and luteinizing hormone\/follicle-stimulating hormone ratio have significance in prognosticating the outcome of in vitro fertilization cycles in polycystic ovary syndrome? J Hum Reprod Sci. 2021;14(1):21\u20137.","journal-title":"J Hum Reprod Sci"},{"issue":"2","key":"6586_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJMoa1705334","volume":"378","author":"Y Shi","year":"2018","unstructured":"Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, et al. Transfer of fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126\u201336.","journal-title":"N Engl J Med"},{"issue":"6","key":"6586_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1513873","volume":"375","author":"ZJ Chen","year":"2016","unstructured":"Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375(6):523.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T04:08:10Z","timestamp":1660363690000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6586"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06586-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial has been approved by the Ethics Committee of Beijing Chaoyang Hospital affiliated to Capital Medical University (No: 2018-SCI-194). Written informed consent will be obtained from all participants. The study will be conducted following the principles outlined in the Declaration of Helsinki and its amendments and the Medical Research Involving Human Subjects Act and will adhere to Good Clinical Practices. The results of this trial will be disseminated through conference presentations and peer-reviewed scientific journals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"654"}}